Biogen Inc. (BIIB) Q1 2022 Earnings Results

Biogen Misses on EPS, Stock Down 0.78%

Biogen's earnings report indicates a disappointing quarter, particularly with the EPS miss. The stock's slight decline of 0.78% reflects investor concerns about the company's performance and market conditions. Without guidance, investors may remain cautious about the company's future prospects.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$3.62	N/A	-17.90%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about the ongoing challenges in the market. They emphasized their focus on strategic priorities and innovation.

We are navigating a challenging environment and remain focused on our strategic priorities.

Our commitment to innovation continues to drive our efforts despite current market conditions.

Biogen Misses on EPS, Stock Down 0.78%

Key numbers

Management commentary

Biogen Inc.

More earnings this week

Biogen Misses on EPS, Stock Down 0.78%

Key numbers

Management commentary